Medicare Orthotics and Prosthetics Patient-Centered Care Act

1) What happened and its current status: Senator Warner (D-VA) introduced S. 2329 on July 17, 2025, in the 119th Congress. The bill has three cosponsors and was referred to the Senate Committee on Finance. An identical companion bill, H.R. 4475, was introduced in the House and referred to the Energy and Commerce and Ways and Means Committees. Both bills remain at the earliest legislative stage—committee referral—with no hearings or markups recorded. The bill is not yet law and faces the standard legislative path: committee consideration, potential floor vote, and bicameral reconciliation with the House companion. 2) The money trail: The bill does not authorize or appropriate any new direct spending. It operates by prohibiting Medicare payment (a 'payment restriction') for O&P devices delivered via drop shipment unless the beneficiary has received fitting training from a qualified practitioner. It also expands the list of practitioners (adding physical therapists, occupational therapists, orthotists, prosthetists) who are exempt from competitive bidding requirements. The financial effect is entirely redistributive: Medicare dollars that currently flow to unqualified drop-ship suppliers must instead flow to credentialed practitioners who provide face-to-face fitting services. The Centers for Medicare & Medicaid Services (CMS) which administers Part B O&P benefits will enforce compliance through claims edits and supplier enrollment standards. 3) Structural winners and losers: The primary commercial beneficiaries are manufacturers and distributors of custom-fabricated orthotics and prosthetics that go through clinical/office-based fitting channels. Zimmer Biomet ($ZBH) and Baxter ($BAX) have material O&P businesses that rely on direct practitioner engagement. Pure-play orthotic/prosthetic manufacturers (none listed on major US exchanges in the data provided; smaller private firms dominate) would benefit most. Losers are mail-order/drop-ship O&P suppliers, largely private, that bypass clinical fitting—these entities will lose Medicare reimbursement eligibility, contracting their addressable market. No significant impact is expected on $STRT (Strattec Security), a security products company with no medical device exposure. 4) Real market data analysis: $ZBH closed at $82.80 on April 28, 2026, down -11.01% over 7 days and -6.51% over 30 days. This price action is severe for a bill introduced nine months ago—the decline is likely driven by broader orthopedics sector headwinds (slowing elective procedure volumes or reimbursement concerns) rather than any legislative signal. $BAX closed at $17.94, down -2.02% over 7 days but up +12.34% over 30 days, showing recent recovery momentum. Neither stock's short-term movement correlates with news on S. 2329; the bill is too early-stage to drive near-term price action. 5) Timeline: The bill must clear the Senate Finance Committee, where it will compete for floor time. Given the 119th Congress runs through January 2027, the bill has ~8 months remaining for a full legislative cycle. The identical House companion provides a path to bicameral passage if momentum builds. However, early-stage healthcare bills in an election year face heavy competition for committee bandwidth. Realistic probability of enactment in the 119th Congress is moderate unless the bill is attached as a legislative rider to must-pass healthcare extenders or year-end omnibus legislation.